“Dosing of the 2nd dose cohort introduced dual intratumoral and...

“Dosing of the 2nd dose cohort introduced dual intratumoral and intraventricular routes of dosing”

This dual-route will fast-track a positive efficacy update and de-risk, with the first intratumoral doses straight into the tumour itself as well as intraventricular. A cathode is inserted to administer the doses into the tumour. Cholortoxin has shown a very good safety profile being already used in humans for imaging technologies.

In the latest boardroom media interview with Jennifer Chow COO, (she's good - confident and from Kite - Bought out by Gilead for 1.8 Billion) Jennifer mentions a 2021 focus on building up the pipeline for other cell therapies and they have been talking to scientists around the world.. Thinking out loud, could we see another license out of City of Hope? Like IMU did with combination virus/Car-t therapy OnCARlytics. Both companies Paul Hopper and both City of hope.

Getting in early, already well into trails prior to listing should see a quick route to FDA IMO. Happy for a steady climb wont be selling for sometime..